Corporate Profile

Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mar 30
2023
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Learn More >
Mar 14
2023
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Learn More >
Mar 02
2023
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Learn More >
Mar 01
2023
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
Learn More >
Feb 28
2023
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Learn More >
Feb 21
2023
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Learn More >
Feb 01
2023
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
Learn More >
Jan 25
2023
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Learn More >
Jan 24
2023
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Learn More >
Jan 17
2023
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Learn More >
View All